Christopher Ezold

June 03, 2021 | The Legal Intelligencer

Many life sciences companies are involved in providing health care, either directly or as a business associate, or are developing products for us by health care providers that create, store or manipulate PHI. This means that these companies must comply with HIPAA, and their services and products must be capable of protecting the PHI with which they deal.

By Christopher Ezold

7 minute read

February 12, 2021 | The Legal Intelligencer

While COVID-19 has had an obviously enormous impact on the American economy and on investing in general, that impact has been less severe in the life sciences sector.

By Christopher Ezold

10 minute read

August 07, 2020 | The Legal Intelligencer

The FDA has taken steps to both accelerate the biotech and life sciences industry's work to test, diagnose and treat COVID-19 as well as rein in misguided or unscrupulous COVID-19 products.

By Christopher Ezold

6 minute read

February 14, 2020 | The Legal Intelligencer

The life sciences and medical technology space is growing rapidly; trends in this space for 2020 reflect this growth. This article addresses the trends to expect, and how that may impact the work their attorneys will be facing in 2020 and beyond.

By Christopher Ezold

6 minute read

August 09, 2019 | The Legal Intelligencer

In 2013, the Federal Department of Health and Human Services (HHS) issued final omnibus amendments to regulations arising under the Health Insurance Portability and Accountability Act (HIPAA).

By Christopher Ezold

6 minute read

June 05, 2019 | The Legal Intelligencer

Since its inception, the Health Insurance Portability and Accountability Act of 1996, (HIPAA) has required that patient health information (PHI) be kept confidential. HIPAA meets this goal primarily through its privacy rule, security rule and breach notification rule.

By Christopher Ezold

7 minute read

April 11, 2019 | The Legal Intelligencer

A question that investors frequently ask of emerging growth life sciences companies is whether they have considered how to monetize the data they will inevitably collect in the development, marketing and sale of their service or product.

By Christopher Ezold

5 minute read

February 19, 2019 | The Legal Intelligencer

If you represent early stage life sciences companies entering the capital markets, you may be asked to opine on the financing and business issues they face. Below is a general overview of some of the issues that you will need to understand to provide solid advice.

By Christopher Ezold

9 minute read